Medical Imaging Corp.

Medical Imaging Corp., through its subsidiaries, provides medical diagnostic imaging services for patients, hospitals and clinics, workers' compensation boards, and insurance companies in North America. It provides remote reading and reporting of medical diagnostic imaging scans. The company also provides magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, nuclear medicine, digital mammography, X-ray, and bone mineral densitometry modalities. As of December 31, 2017, it operated an independent diagnostic imaging facility in Pottsville, Pennsylvania; and three diagnostic centers in Florida. The company was formerly known as Diagnostic Imaging International Corp. and changed its name to Medical Imaging Corp. in July 2014. Medical Imaging Corp. was incorporated in 2000 and is based in Las Vegas, Nevada.

Medical Imaging Corp. trades as MEDD on OTC. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in USD.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $7.22M of revenue and -$3.02M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Medical Imaging Corp. can be compared against peers such as Decision Diagnostics Corp., Endonovo Therapeutics, Inc., Filament Health Corp., Integrative Health Technologies, Inc., Itoco Inc., Nutranomics, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $31,910, beta of 4.40, and return on equity of +56.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MEDD currently shows total debt of $3.83M and beta of 4.40. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.medimagingcorp.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.